Caisse DE Depot ET Placement DU Quebec Has $3.88 Million Position in Regeneron Pharmaceuticals, Inc. (REGN)

Caisse DE Depot ET Placement DU Quebec lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,649 shares of the biopharmaceutical company’s stock after acquiring an additional 200 shares during the period. Caisse DE Depot ET Placement DU Quebec’s holdings in Regeneron Pharmaceuticals were worth $3,883,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the stock. Fieldpoint Private Securities LLC purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth about $130,000. Sterling Investment Advisors Ltd. raised its position in Regeneron Pharmaceuticals by 11.2% in the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 28 shares during the period. FNY Partners Fund LP raised its position in Regeneron Pharmaceuticals by 200.0% in the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 200 shares during the period. IFP Advisors Inc raised its position in Regeneron Pharmaceuticals by 33.2% in the 2nd quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 96 shares during the period. Finally, Virtu KCG Holdings LLC purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth about $206,000. 66.67% of the stock is owned by hedge funds and other institutional investors.

A number of research firms recently weighed in on REGN. Citigroup reissued a “buy” rating and issued a $575.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Thursday, September 7th. Raymond James Financial reissued an “outperform” rating and issued a $566.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, September 6th. Morgan Stanley reissued an “equal weight” rating and issued a $450.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 23rd. BidaskClub raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 24th. Finally, J P Morgan Chase & Co reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, August 15th. Two equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $467.84.

Regeneron Pharmaceuticals, Inc. (REGN) opened at $380.78 on Monday. The company has a market cap of $40,910.00, a P/E ratio of 32.97, a PEG ratio of 1.50 and a beta of 1.53. Regeneron Pharmaceuticals, Inc. has a 1 year low of $340.09 and a 1 year high of $543.55. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, topping the Zacks’ consensus estimate of $3.83 by $0.16. The business had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.45 billion. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The company’s quarterly revenue was up 23.0% compared to the same quarter last year. During the same period last year, the company posted $3.13 earnings per share. research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 13.55 EPS for the current year.

In related news, Director Michael S. Brown sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $475.00, for a total transaction of $712,500.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Charles A. Baker sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $450.00, for a total transaction of $900,000.00. Following the transaction, the director now directly owns 11,000 shares in the company, valued at $4,950,000. The disclosure for this sale can be found here. Company insiders own 10.80% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Caisse DE Depot ET Placement DU Quebec Has $3.88 Million Position in Regeneron Pharmaceuticals, Inc. (REGN)” was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://transcriptdaily.com/2017/12/11/caisse-de-depot-et-placement-du-quebec-has-3-88-million-position-in-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply